Back to Search Start Over

Keymed Biosciences Announced Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM

Source :
Plus Company Updates. June 24, 2024
Publication Year :
2024

Abstract

CHENGDU: Keymed Biosciences Inc. (HKEX: 02162) announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research paper entitled A [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
Plus Company Updates
Publication Type :
News
Accession number :
edsgcl.800430315